TCRX · Company research
TScan Therapeutics, Inc. Common Stock (TCRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine | Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis Kalkine | View source ↗ | Kalkine | Oct 2, 2026 | neutral | 0 | 0.6 |
| TScan Therapeutics Announces Executive Departures Amid Reorganization - The Globe and Mail | TScan Therapeutics Announces Executive Departures Amid Reorganization The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| A CEO receives stock with 75% conditionally vesting on a trial milestone or in 2030 at TScan Therapeutics (TCRX). - Stock Titan | A CEO receives stock with 75% conditionally vesting on a trial milestone or in 2030 at TScan Therapeutics (TCRX). Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Three parties report shared voting power over more than 5% of TScan Therapeutics (TCRX). - Stock Titan | Three parties report shared voting power over more than 5% of TScan Therapeutics (TCRX). Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction - Benzinga | TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction Benzinga | View source ↗ | Benzinga | Sep 2, 2026 | neutral | 0 | 0.6 |
| TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan | TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration Stock Titan | View source ↗ | Stock Titan | Aug 18, 2026 | neutral | 0 | 0.6 |
| TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance | TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| TScan Therapeutics Reports $30.4 Million Q2 Net Loss | TCRX Stock News - Quiver Quantitative | TScan Therapeutics Reports $30.4 Million Q2 Net Loss | TCRX Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative | TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| TCRX Forecast — Price Target — Prediction for 2027 - TradingView | TCRX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| TScan Therapeutics to speak at H.C. Wainwright cell therapy event June 30 - Stock Titan | TScan Therapeutics to speak at H.C. Wainwright cell therapy event June 30 Stock Titan | View source ↗ | Stock Titan | Jun 24, 2026 | neutral | 0 | 0.6 |
| TCRX - Finviz | TCRX Finviz | View source ↗ | Finviz | May 28, 2026 | neutral | 0 | 0.6 |
| TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance | TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | May 6, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 22, 2024 | neutral | 0 | 0.6 |
| TCRX: Tscan Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | TCRX: Tscan Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Mar 22, 2017 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.